Venetoclax-Dexamethasone VersusPomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Popat R, et al.
Journal of Clinical Oncology
December 2025
Authors and Affiliates
Rakesh Popat, MD, PhD1 ; Meral Beksac, MD2 ; Meletios A. Dimopoulos, MD3,4 ; Moshe E. Gatt, MD5 ; Francesca Gay, MD6 ;Jae-Cheol Jo, MD, PhD7 ; Prashant Kapoor, MD8 ; Eirini Katodritou, MD, PhD9 ; K. Martin Kort¨um, MD10 ; Silvia Ling, PhD, MBBS11 ;Chandramouli Nagarajan, MD12 ; Kenshi Suzuki, MD, PhD13; Lugui Qiu, MD14; Maika Onishi, MD15; Grace Ku, MD15 ; Monique Dail, PhD15 ;Nabanita Mukherjee, PhD16; Jeremy A. Ross, PhD16; Mohamed Ali Badawi, PhD16; Mary Jean Fusco, MD16; Edyta Dobkowska, MD17;Emma Arriola, PhD18; Orlando F. Bueno, MD, PhD16; Nizar J. Bahlis, MD19 ; Shinsuke Iida, MD20 ; Philippe Moreau, MD21; Jason Valent, MD22; andMar´ıa-Victoria Mateos, MD, PhD231Haematology Department, University College London Hospitals NHSFoundation Trust, London, United Kingdom2Department of Hematology, Ankara University, Ankara, Turkey3Department of Clinical Therapeutics, School of Medicine, National andKapodistrian University of Athens, Athens, Greece4Department of Medicine, Korea University, Seoul, South Korea5Department of Hematology, Hadassah Hebrew University MedicalCenter, Jerusalem, Israel6Division of Hematology 1, Department of Biotechnology and HealthScience, Azienda Ospedaliero-Universitaria Citt `a della Salute e dellaScienza, University of Torino, Torino, Italy7Department of Hematology and Oncology, Ulsan University Hospital,University of Ulsan College of Medicine, Ulsan, Korea8Division of Hematology, Mayo Clinic, Rochester, MN9Department of Hematology, Theagenion Cancer Hospital, Thessaloniki,Greece 10Department of Internal Medicine II, W¨urzburg University Hospital,University of W¨urzburg, W¨urzburg, Germany11Department of Haematology, Liverpool Hospital, Sydney, NSW,Australia12Department of Haematology, Singapore General Hospital, Singapore,Singapore13Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,Tokyo, Japan14National Clinical Research Center for Hematological Disorders & StateKey Laboratory of Experimental Hematology, Institute of Hematologyand Blood Diseases Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Tianjin, China15Genentech Inc, South San Francisco, CA16AbbVie Inc, North Chicago, IL17Pharmacyclics Switzerland GmbH, An AbbVie Company,Schaffhausen, Switzerland18AbbVie, Maidenhead, United Kingdom19Arnie Charbonneau Cancer Institute, University of Calgary, Calgary,AB, Canada20Department of Hematology and Oncology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japan21Department of Hematology, University Hospital Hˆotel-Dieu, Nantes,France22Department of Hematology and Medical Oncology, Cleveland ClinicFoundation, Taussig Cancer Institute, Cleveland, OH23Haematology Department, University Hospital of Salamanca, Institutode Investigaci ´on Biom´edica de Salamanca and Institute of CancerMolecular and Cellular Biology and CIBERONC, Salamanca, Spain